Many adults with asthma still struggle with daily symptoms even when using standard inhalers and medications. A new review suggests a traditional Chinese herbal formula called Yupingfeng powder may help when added to usual care. The combination led to better symptom control and improved lung function in adults with bronchial asthma.
Bronchial asthma affects millions of adults worldwide. It causes wheezing, coughing, chest tightness, and shortness of breath. Standard treatments include inhaled steroids and bronchodilators. These help many people, but some still have breakthrough symptoms or side effects. Patients often look for safe add-on options that can improve day-to-day control.
But here is the twist. Researchers combined data from multiple clinical trials to see if adding Yupingfeng powder to standard therapy makes a real difference. Yupingfeng powder is a classic Chinese herbal formula. It contains astragalus, atractylodes, and saposhnikovia. The goal was to see if this combination improves outcomes without adding safety risks.
Think of asthma control like managing traffic in a busy city. Standard medications act like traffic lights and detours that open up the airways. Yupingfeng powder may act like a city planner who reduces overall congestion by supporting the body’s defenses. This herbal blend is often used to support immune balance and reduce inflammation. In asthma, calming the immune response can help keep airways less reactive.
The review followed strict methods. The authors searched seven medical databases up to October 2025. They included 20 randomized trials with 1,896 adults. All studies compared Yupingfeng powder plus standard therapy against standard therapy alone. The researchers assessed study quality and used statistical tools to combine results. They also looked at sources of variation across the studies.
The results were clear. Adding Yupingfeng powder to standard therapy increased the overall clinical response rate. In plain terms, more people felt better. The overall response rate was about 87 percent with the combination versus about 72 percent with standard therapy alone. That is an absolute risk reduction of 14.5 percent. Lung function measures improved as well. These include FEV1, FVC, FEV1/FVC ratio, and peak flow. Asthma control test scores also improved.
But there is a catch. The studies were small and not all were high quality. Some were done in similar regions, which limits how broadly the results apply. The review found that differences in treatment length and study year explained some of the variation in results. This means the findings are promising but not definitive.
An expert perspective from the field notes that this review used modern methods to address older data. The authors followed PRISMA 2020 guidelines and registered the protocol. They used standard tools to check study quality and statistical methods to explore heterogeneity. This adds credibility, but the evidence still needs stronger trials.
This does not mean Yupingfeng powder is ready for everyone right now.
If you have asthma and are considering herbal options, talk with your doctor. Ask whether adding a traditional formula like Yupingfeng powder could fit your treatment plan. Do not stop or change your current medications without medical guidance. The combination appears safe in the reviewed studies, with only mild issues like stomach discomfort or dry mouth reported. Serious side effects were not seen, but larger studies are needed to confirm safety.
The studies included in this review had some limitations. Many were small and not double blinded. Most were done in China, which may limit generalizability. Adverse event reporting was limited, and long-term safety data are not yet robust. These gaps mean clinicians should use caution when considering this add-on therapy.
What happens next. Researchers need large, high-quality trials with double-blind designs and placebo controls. Longer follow-up will help confirm lasting benefits and safety. Regulatory agencies may require more data before approving this combination for asthma care. Until then, the evidence suggests potential benefit, but it is not yet definitive.
ClinicalPulse is committed to clear, trustworthy medical journalism. This article summarizes current research and is not a substitute for professional medical advice.
